Collected from 105 procedures across 37 U.S. centers and 41 physicians, the preference test revealed:

• 95% of physicians reported that SOFIA™ 88 catheter reliably reached the target location—even in anatomically challenging cases, with 59% of procedures in ICA-T or beyond
• 86% of physicians rated the SOFIA™ 88 catheter as “Better” or “Much Better” than alternatives overall
• Physician data included: SOFIA™ 88 catheter outperformed the ZOOM 88 catheter in 94% of cases and the HiPoint 88 catheter in 79%

“These real-world results further validate SOFIA™ 88 catheter’s position as a leading super-bore support catheter,” said Carsten Schroeder, President and CEO of Terumo Neuro. “This new dataset reinforces what we’ve heard consistently from physicians: the SOFIA™ 88 catheter delivers reliable performance where it matters most. We are proud to see the catheter outperform other large-bore devices in real-world settings—and even more proud that this innovation was shaped through close physician partnership. It reflects our long-standing commitment to delivering meaningful neurovascular advancements rooted in evidence, experience, and collaboration.”